196 related articles for article (PubMed ID: 17607967)
21. Angiogenesis, angiogenic factor expression and hematological malignancies.
Ribatti D; Vacca A; De Falco G; Roccaro A; Roncali L; Dammacco F
Anticancer Res; 2001; 21(6B):4333-9. PubMed ID: 11908688
[TBL] [Abstract][Full Text] [Related]
22. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
23. Angiogenesis and antiangiogenic therapy in hematologic malignancies.
Dong X; Han ZC; Yang R
Crit Rev Oncol Hematol; 2007 May; 62(2):105-18. PubMed ID: 17188504
[TBL] [Abstract][Full Text] [Related]
24. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
Shibuya M
FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071
[TBL] [Abstract][Full Text] [Related]
25. Targeting vessels to treat hepatocellular carcinoma.
Romanque P; Piguet AC; Dufour JF
Clin Sci (Lond); 2008 Apr; 114(7):467-77. PubMed ID: 18302534
[TBL] [Abstract][Full Text] [Related]
26. The role of angiogenesis in the biology and therapy of myelodysplastic syndromes.
Aguayo A
Curr Hematol Rep; 2004 May; 3(3):184-91. PubMed ID: 15087066
[TBL] [Abstract][Full Text] [Related]
27. Molecular angiogenic signaling in angiofibromas after embolization: implications for therapy.
Ngan BY; Forte V; Campisi P
Arch Otolaryngol Head Neck Surg; 2008 Nov; 134(11):1170-6. PubMed ID: 19015446
[TBL] [Abstract][Full Text] [Related]
28. VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE.
Roscoe WA; Welsh ME; Carter DE; Karlik SJ
J Neuroimmunol; 2009 Apr; 209(1-2):6-15. PubMed ID: 19233483
[TBL] [Abstract][Full Text] [Related]
29. The distribution of angiopoietin-1, angiopoietin-2 and their receptors tie-1 and tie-2 in the very early human placenta.
Seval Y; Sati L; Celik-Ozenci C; Taskin O; Demir R
Placenta; 2008 Sep; 29(9):809-15. PubMed ID: 18675456
[TBL] [Abstract][Full Text] [Related]
30. Antiangiogenesis in haematological malignancies.
Li WW; Hutnik M; Gehr G
Br J Haematol; 2008 Dec; 143(5):622-31. PubMed ID: 19036013
[TBL] [Abstract][Full Text] [Related]
31. The role of vascular endothelial growth factors and their receptors in malignant melanomas.
Brychtova S; Bezdekova M; Brychta T; Tichy M
Neoplasma; 2008; 55(4):273-9. PubMed ID: 18505336
[TBL] [Abstract][Full Text] [Related]
32. Targeting tumor angiogenesis.
Gaur P; Bose D; Samuel S; Ellis LM
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S12-9. PubMed ID: 19393831
[TBL] [Abstract][Full Text] [Related]
33. [Angiogenesis and endothelial cells in blood neoplasms].
Usnarska-Zubkiewicz L; Poreba M; Kuliczkowski K
Przegl Lek; 2006; 63(3):146-50. PubMed ID: 16969900
[TBL] [Abstract][Full Text] [Related]
34. VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice.
Ou XM; Li WC; Liu DS; Li YP; Wen FQ; Feng YL; Zhang SF; Huang XY; Wang T; Wang K; Wang X; Chen L
Int Immunopharmacol; 2009 Jan; 9(1):70-9. PubMed ID: 18976720
[TBL] [Abstract][Full Text] [Related]
35. Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia.
Barbarroja N; Torres LA; Luque MJ; Carretero RM; Valverde-Estepa A; Lopez-Sanchez LM; Rodriguez-Ariza A; Velasco F; Torres A; López-Pedrera C
Exp Hematol; 2009 Jun; 37(6):679-91. PubMed ID: 19463770
[TBL] [Abstract][Full Text] [Related]
36. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.
Fernando NT; Koch M; Rothrock C; Gollogly LK; D'Amore PA; Ryeom S; Yoon SS
Clin Cancer Res; 2008 Mar; 14(5):1529-39. PubMed ID: 18316578
[TBL] [Abstract][Full Text] [Related]
37. Anti-angiogenic effects of ribonucleic acid interference targeting vascular endothelial growth factor and hypoxia-inducible factor-1alpha.
Forooghian F; Das B
Am J Ophthalmol; 2007 Nov; 144(5):761-8. PubMed ID: 17869204
[TBL] [Abstract][Full Text] [Related]
38. Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
Podar K; Anderson KC
Curr Cancer Drug Targets; 2011 Nov; 11(9):1005-24. PubMed ID: 21933109
[TBL] [Abstract][Full Text] [Related]
39. [VEGF, anti-vEGF and diseases].
Corvol P
Bull Acad Natl Med; 2008 Feb; 192(2):289-300; discussion 300-2. PubMed ID: 18819684
[TBL] [Abstract][Full Text] [Related]
40. Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
Cao Y
Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]